Inflammation-based different association between anatomical severity of coronary artery disease and lung cancer

Ya-Wei ZHAO; Kai-Xin YAN; Ming-Zhuang SUN; Yi-Hao WANG; Yun-Dai CHEN; Shun-Ying HU

doi:10.11909/j.issn.1671-5411.2022.08.003

Volume 19 Issue 8

Aug. 2022

Turn off MathJax

Article Contents

Article Navigation > Journal of Geriatric Cardiology > 2022 > 19(8): 575-582

Ya-Wei ZHAO, Kai-Xin YAN, Ming-Zhuang SUN, Yi-Hao WANG, Yun-Dai CHEN, Shun-Ying HU. Inflammation-based different association between anatomical severity of coronary artery disease and lung cancer. J Geriatr Cardiol 2022; 19(8): 575-582. doi: 10.11909/j.issn.1671-5411.2022.08.003

Citation:

Ya-Wei ZHAO, Kai-Xin YAN, Ming-Zhuang SUN, Yi-Hao WANG, Yun-Dai CHEN, Shun-Ying HU. Inflammation-based different association between anatomical severity of coronary artery disease and lung cancer. J Geriatr Cardiol 2022; 19(8): 575-582. doi: 10.11909/j.issn.1671-5411.2022.08.003

Citation:

Ya-Wei ZHAO, Kai-Xin YAN, Ming-Zhuang SUN, Yi-Hao WANG, Yun-Dai CHEN, Shun-Ying HU. Inflammation-based different association between anatomical severity of coronary artery disease and lung cancer. J Geriatr Cardiol 2022; 19(8): 575-582. doi: 10.11909/j.issn.1671-5411.2022.08.003

PDF( 6489 KB)

Inflammation-based different association between anatomical severity of coronary artery disease and lung cancer

doi: 10.11909/j.issn.1671-5411.2022.08.003

Ya-Wei ZHAO^{1, 2, *},
Kai-Xin YAN^{1, 2, *},
Ming-Zhuang SUN^{1, 2},
Yi-Hao WANG^{1, 2},
Yun-Dai CHEN¹,
Shun-Ying HU^{1
,
,}

1.
Department of Cardiology, Chinese PLA General Hospital, Beijing, China
2.
Medical School of Chinese PLA, Beijing, China

^*The authors contributed equally to this manuscript

More Information

Corresponding author: hsylily@163.com
Available Online: 2022-08-19
Publish Date: 2022-08-28

Abstract

Abstract

BACKGROUND Coronary artery disease (CAD) is associated with cancer. The role of inflammation in the association of CAD with cancer remains unclear. The study investigated whether inflammation could impact the relationship between CAD and lung cancer. METHODS The study involved 96 newly diagnosed lung cancer patients without receiving anti-cancer therapy and 288 matched non-cancer patients. All the patients underwent coronary angiography and were free from previous percutaneous coronary intervention or coronary artery bypass grafting. SYNTAX score (SXscore) were used to assess severity of CAD. High SXscore (SXhigh) grade was defined as SXscore > 16 (highest quartile). Neutrophil-to-lymphocyte ratio (NLR) served as an inflammatory biomarker. NLR-high grade referred to NLR > 2.221 (median). RESULTS Among 384 study patients, 380 patients (98.96%) had NLR value (median: 2.221, interquartile range: 1.637–3.040). Compared to non-cancer patients, lung cancer patients had higher rate of SXhigh among total study patients (P = 0.014) and among patients with NLR-high (P = 0.006), but had not significantly higher rate of SXhigh among patients with NLR-low (P = 0.839). Multivariate logistic regression analysis showed that SXhigh was associated with lung cancer [odds ratio (OR) = 1.834, 95% CI: 1.063–3.162, P = 0.029]. Subgroup analysis showed that SXhigh was associated with lung cancer among patients with NLR-high (OR = 2.801, 95% CI: 1.355–5.794, P = 0.005), however, the association between SXhigh and lung cancer was not significant among patients with NLR-low (OR = 0.897, 95% CI: 0.346–2.232, P = 0.823). CONCLUSIONS Inflammation could lead different association between anatomical severity of CAD and lung cancer. Severity of CAD was significantly associated with increased risk of lung cancer among patients with high inflammation rather than among patients with low inflammation.

FullText(HTML)

References(35)

References

[1]	Tapia-Vieyra JV, Delgado-Coello B, Mas-Oliva J. Atherosclerosis and cancer: a resemblance with far-reaching implications. Arch Med Res 2017; 48: 12−26. doi: 10.1016/j.arcmed.2017.03.005
[2]	Handy CE, Quispe R, Pinto X, et al. Synergistic opportunities in the interplay between cancer screening and cardiovascular disease risk assessment: together we are stronger. Circulation 2018; 138: 727−734. doi: 10.1161/CIRCULATIONAHA.118.035516
[3]	Suzuki M, Tomoike H, Sumiyoshi T, et al. Incidence of cancers in patients with atherosclerotic cardiovascular diseases. Int J Cardiol Heart Vasc 2017; 17: 11−16. doi: 10.1016/j.ijcha.2017.08.004
[4]	Kim BJ, Kim JY, Chang DK, et al. Coexistence between carotid artery stenosis and colorectal adenomatous polyps in middle-aged men. Digestion 2010; 81: 20−26. doi: 10.1159/000217451
[5]	Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin 2016; 66: 115−132. doi: 10.3322/caac.21338
[6]	Sun M, Yang Q, Li M, et al. Association between the severity of coronary artery disease and lung cancer: a pilot cross-sectional study. Arq Bras Cardiol 2022; 118: 478−485. doi: 10.36660/abc.20200478
[7]	Raposeiras Roubín S, Cordero A. The two-way relationship between cancer and atherosclerosis. Rev Esp Cardiol (Engl Ed) 2019; 72: 487−494. doi: 10.1016/j.recesp.2018.12.011
[8]	Sandfeld-Paulsen B, Meldgaard P, Sorensen BS, et al. The prognostic role of inflammation-scores on overall survival in lung cancer patients. Acta Oncol 2019; 58: 371−376. doi: 10.1080/0284186X.2018.1546057
[9]	Mantovani A, Allavena P, Sica A, et al. Cancer-related inflammation. Nature 2008; 454: 436−444. doi: 10.1038/nature07205
[10]	Libby P. Inflammation in atherosclerosis. Nature 2002; 420: 868−874. doi: 10.1038/nature01323
[11]	Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med 2017; 377: 1119−1131. doi: 10.1056/NEJMoa1707914
[12]	Ridker PM, MacFadyen JG, Thuren T, et al. Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial. Lancet 2017; 390: 1833−1842. doi: 10.1016/S0140-6736(17)32247-X
[13]	Aleksandrova K, Mozaffarian D, Pischon T. Addressing the perfect storm: biomarkers in obesity and pathophysiology of cardiometabolic risk. Clin Chem 2018; 64: 142−153. doi: 10.1373/clinchem.2017.275172
[14]	Suárez-Cuenca JA, Ruíz-Hernández AS, Mendoza-Castañeda AA, et al. Neutrophil-to-lymphocyte ratio and its relation with pro-inflammatory mediators, visceral adiposity and carotid intima-media thickness in population with obesity. Eur J Clin Invest 2019; 49: e13085. doi: 10.1111/eci.13085
[15]	Horne BD, Anderson JL, John JM, et al. Which white blood cell subtypes predict increased cardiovascular risk? J Am Coll Cardiol 2005; 45: 1638−1643. doi: 10.1016/j.jacc.2005.02.054
[16]	Zuin M, Rigatelli G, Picariello C, et al. Correlation and prognostic role of neutrophil to lymphocyte ratio and SYNTAX score in patients with acute myocardial infarction treated with percutaneous coronary intervention: a six-year experience. Cardiovasc Revasc Med 2017; 18: 565−571. doi: 10.1016/j.carrev.2017.05.007
[17]	Sönmez O, Ertaş G, Bacaksız A, et al. Relation of neutrophil-to-lymphocyte ratio with the presence and complexity of coronary artery disease: an observational study. Anadolu Kardiyol Derg 2013; 13: 662−667. doi: 10.5152/akd.2013.188
[18]	Prats-Puig A, Gispert-Saüch M, Díaz-Roldán F, et al. Neutrophil-to-lymphocyte ratio: an inflammation marker related to cardiovascular risk in children. Thromb Haemost 2015; 114: 727−734. doi: 10.1160/TH15-01-0037
[19]	Berkovitch A, Younis A, Grossman Y, et al. Relation of neutrophil to lymphocyte ratio to risk of incident atrial fibrillation. Am J Cardiol 2019; 123: 396−401. doi: 10.1016/j.amjcard.2018.10.036
[20]	Hu S, Gao H, Zhang J, et al. Association between radiotherapy and anatomic severity of coronary artery disease: a propensity score matching comparison among adult-onset thoracic cancer survivors. Cardiology 2018; 140: 239−246. doi: 10.1159/000492108
[21]	Yang Q, Chen Y, Gao H, et al. Chemotherapy-related anatomical coronary artery disease in lung cancer patients evaluated by coronary angiography SYNTAX score. Arq Bras Cardiol 2020; 114: 1004−1012. doi: 10.36660/abc.20190201
[22]	Gaudino M, Hameed I, Di Franco A, et al. Comparison of SYNTAX score strata effects of percutaneous and surgical revascularization trials: a meta-analysis. J Thorac Cardiovasc Surg 2021; 2: S0022-5223(21)00881-3. doi: 10.1016/j.jtcvs.2021.05.036
[23]	Rodriguez AE, Fernandez-Pereira C, Mieres J, et al. Modifying angiographic SYNTAX score according to PCI strategy: lessons learnt from ERACI IV study. Cardiovasc Revasc Med 2015; 16: 418−420. doi: 10.1016/j.carrev.2015.07.001
[24]	Wykrzykowska JJ, Garg S, Girasis C, et al. Value of the SYNTAX score for risk assessment in the all-comers population of the randomized multicenter LEADERS (Limus Eluted from A Durable versus ERodable Stent coating) trial. J Am Coll Cardiol 2010; 56: 272−277. doi: 10.1016/j.jacc.2010.03.044
[25]	Sianos G, Morel MA, Kappetein AP, et al. The SYNTAX score: an angiographic tool grading the complexity of coronary artery disease. EuroIntervention 2005; 1: 219−227. doi: 10.1182/blood-2006-09-048868
[26]	Malmborg M, Christiansen CB, Schmiegelow MD, et al. Incidence of new onset cancer in patients with a myocardial infarction: a nationwide cohort study. BMC Cardiovasc Disord 2018; 18: 198. doi: 10.1186/s12872-018-0932-z
[27]	Kim J, Lee JY, Ham NS, et al. Association between carotid ultrasonography findings and colorectal adenoma in asymptomatic adults. Dig Dis Sci 2020; 65: 1816−1828. doi: 10.1007/s10620-019-05899-7
[28]	Kondapalli L, Moslehi J, Bonaca MP. Inflammation begets inflammation: cancer and acute MI. Eur Heart J 2020; 41: 2194−2196. doi: 10.1093/eurheartj/ehz951
[29]	McAllister SS, Weinberg RA. The tumour-induced systemic environment as a critical regulator of cancer progression and metastasis. Nat Cell Biol 2014; 16: 717−727. doi: 10.1038/ncb3015
[30]	Koelwyn GJ, Newman AAC, Afonso MS, et al. Myocardial infarction accelerates breast cancer via innate immune reprogramming. Nat Med 2020; 26: 1452−1458. doi: 10.1038/s41591-020-0964-7
[31]	Khansari N, Shakiba Y, Mahmoudi M. Chronic inflammation and oxidative stress as a major cause of age-related diseases and cancer. Recent Pat Inflamm Allergy Drug Discov 2009; 3: 73−80. doi: 10.2174/187221309787158371
[32]	Prasad S, Sung B, Aggarwal BB. Age-associated chronic diseases require age-old medicine: role of chronic inflammation. Prev Med 2012; 54: S29−S37. doi: 10.1016/j.ypmed.2011.11.011
[33]	Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005; 352: 1685−1695. doi: 10.1056/NEJMra043430
[34]	Pant S, Deshmukh A, Gurumurthy GS, et al. Inflammation and atherosclerosis-revisited. J Cardiovasc Pharmacol Ther 2014; 19: 170−178. doi: 10.1177/1074248413504994
[35]	Cho WC, Kwan CK, Yau S, et al. The role of inflammation in the pathogenesis of lung cancer. Expert Opin Ther Targets 2011; 15: 1127−1137. doi: 10.1517/14728222.2011.599801